Shin Nippon Biomedical Laboratories (2395) Earnings: Net Income Soars 308.6% YoY to 1.064 Billion Yen

Shin Nippon Biomedical Laboratories (2395) released its financial results, reporting net income attributable to owners of the parent of 1.064 billion yen, a significant increase of 308.6% compared to the same period of the previous year. Net sales reached 7.868 billion yen, up 21.5% year-on-year, while ordinary income surged 177.9% to 1.433 billion yen. Operating income stood at 0.521 billion yen, reflecting steady growth in core business profitability.

Examining the financial foundation and efficiency, the equity ratio is 41.6%, maintaining a stable capital structure, with retained earnings accumulated at 22.33 billion yen against interest-bearing debt of 37.58 billion yen. Return on Equity (ROE) stands at 3.09% and Return on Assets (ROA) is 1.06%, with basic earnings per share (EPS) recorded at 25.55 yen. Overall, the financial results demonstrate robust profit expansion across key metrics.